Capecitabine News and Research

RSS
Bevacizumab ruled out for stage III colorectal cancer

Bevacizumab ruled out for stage III colorectal cancer

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Advanced breast cancer that has spread to the brain could be treated with drug combination

Advanced breast cancer that has spread to the brain could be treated with drug combination

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer

Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer

Study examines whether eribulin offers added benefit to women with breast cancer

Study examines whether eribulin offers added benefit to women with breast cancer

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

New Gateway-funded phase II ADAPT study for metastatic colorectal cancer

New Gateway-funded phase II ADAPT study for metastatic colorectal cancer

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

Investigational drug slows metastatic breast cancer progression

Investigational drug slows metastatic breast cancer progression

T-DM1 better than standard therapy in controlling breast cancer

T-DM1 better than standard therapy in controlling breast cancer

Aeterna Zentaris announces results from perifosine Phase 3 trial on colorectal cancer

Aeterna Zentaris announces results from perifosine Phase 3 trial on colorectal cancer

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Vaccine injections given directly into pancreatic cancer tumors associated with stable disease

Vaccine injections given directly into pancreatic cancer tumors associated with stable disease

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Yakult Honsha commences perifosine Phase 1/2 trial for refractory advanced colorectal cancer in Japan

Yakult Honsha commences perifosine Phase 1/2 trial for refractory advanced colorectal cancer in Japan